X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA GLENMARK PHARMA ELDER PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x -0.2 13.5 - View Chart
P/BV x 0.1 3.8 2.7% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 ELDER PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
GLENMARK PHARMA
Mar-16
ELDER PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs3801,262 30.1%   
Low Rs188672 28.0%   
Sales per share (Unadj.) Rs491.2270.6 181.6%  
Earnings per share (Unadj.) Rs-3.224.9 -12.8%  
Cash flow per share (Unadj.) Rs14.434.4 41.9%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs376.5151.3 248.8%  
Shares outstanding (eoy) m20.54282.16 7.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.63.6 16.2%   
Avg P/E ratio x-89.338.9 -229.7%  
P/CF ratio (eoy) x19.728.1 70.2%  
Price / Book Value ratio x0.86.4 11.8%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m5,833272,778 2.1%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m2,17913,782 15.8%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m10,08976,340 13.2%  
Other income Rs m257356 72.0%   
Total revenues Rs m10,34676,696 13.5%   
Gross profit Rs m-79214,172 -5.6%  
Depreciation Rs m3612,691 13.4%   
Interest Rs m2,7561,789 154.1%   
Profit before tax Rs m-3,65310,048 -36.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1253,028 4.1%   
Profit after tax Rs m-657,019 -0.9%  
Gross profit margin %-7.818.6 -42.3%  
Effective tax rate %-3.430.1 -11.4%   
Net profit margin %-0.69.2 -7.0%  
BALANCE SHEET DATA
Current assets Rs m9,24059,096 15.6%   
Current liabilities Rs m9,99840,018 25.0%   
Net working cap to sales %-7.525.0 -30.0%  
Current ratio x0.91.5 62.6%  
Inventory Days Days4675 61.8%  
Debtors Days Days60119 50.3%  
Net fixed assets Rs m10,12439,075 25.9%   
Share capital Rs m206282 72.9%   
"Free" reserves Rs m5,58230,281 18.4%   
Net worth Rs m7,73442,703 18.1%   
Long term debt Rs m4,88924,873 19.7%   
Total assets Rs m22,882111,026 20.6%  
Interest coverage x-0.36.6 -4.9%   
Debt to equity ratio x0.60.6 108.5%  
Sales to assets ratio x0.40.7 64.1%   
Return on assets %11.87.9 148.2%  
Return on equity %-0.816.4 -5.1%  
Return on capital %22.317.5 127.4%  
Exports to sales %3.043.3 7.0%   
Imports to sales %0.47.4 5.7%   
Exports (fob) Rs m30733,044 0.9%   
Imports (cif) Rs m435,672 0.8%   
Fx inflow Rs m30736,945 0.8%   
Fx outflow Rs m12561,066 0.2%   
Net fx Rs m181-24,122 -0.8%   
CASH FLOW
From Operations Rs m11,7543,449 340.8%  
From Investments Rs m-561-8,802 6.4%  
From Financial Activity Rs m-6,7626,986 -96.8%  
Net Cashflow Rs m4,432934 474.6%  

Share Holding

Indian Promoters % 39.6 48.3 82.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 6.9 108.7%  
FIIs % 16.8 34.4 48.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.5 343.8%  
Shareholders   16,479 56,727 29.0%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   CIPLA  PFIZER  ALKEM LABORATORIES  ORCHID PHARMA LTD  SANOFI INDIA  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS